肝细胞癌患者DEB-TACE中SACE评分与肿瘤缓解的相关性及其对生存的影响
回顾性单中心研究纳入50例不可切除肝细胞癌患者,于2010年1月至2015年7月接受DEB-TACE,评估术中SACE评分与术后mRECIST肿瘤缓解及生存的关系。SACE评分与局部及整体mRECIST缓解显著相关,并与门静脉期相对肿瘤密度呈负相关;mRECIST独立预测总生存,但SACE对无进展生存或总生存无直接影响。
要点
- SACE评分与DEB-TACE术后局部及整体mRECIST缓解显著相关。
- mRECIST完全缓解较进展性疾病独立预测更长的总生存。
- SACE评分对无进展生存或总生存无直接影响。
核心结论
- SACE评分对无进展生存或总生存无直接影响,但SACE评分与局部及整体mRECIST肿瘤缓解显著相关,而mRECIST缓解又显著预测总生存,作者据此推测SACE对总生存有间接影响,并认为应尝试完全栓塞。
研究设计与样本
- 回顾性单中心研究,纳入50例不可切除肝细胞癌患者,于2010年1月至2015年7月接受DEB-TACE。
- 术中血管造影终点采用SACE量表分类,计算DEB-TACE前后动脉期(DArt)和门静脉期(DPV)CT相对肿瘤密度。
- 肿瘤缓解按mRECIST评估,采用单因素Kaplan-Meier和Cox回归分析。
关键影像表现/征象
- SACE评分I、II、III、IV级分别见于1例(2%)、20例(40%)、15例(30%)和14例(28%)患者。
- SACE评分与DPV呈负相关(p=0.005,r=-0.40)。
- mRECIST进展性疾病以及DArt和DPV升高与无进展生存显著缩短相关。
诊断标准与关键数值
- SACE评分与局部mRECIST结果显著相关(p<0.001,r=0.49),与整体mRECIST结果显著相关(p=0.042,r=0.29)。
- mRECIST独立预测总生存,完全缓解 versus 进展性疾病的风险比为0.15(95%CI 0.03-0.68,p=0.014)。
临床应用与阅片要点
- 作者认为应尝试完全栓塞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To asses angiographic and computed tomographic success criteria during and after transcatheter arterial drug-eluting bead chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC) and its impact on progression-free survival (PFS) and overall survival (OS).
METHODS: In this retrospective single-center study, 50 patients with unresectable HCC having undergone DEB-TACE from January 2010 to July 2015 were assessed. The angiographic endpoint was classified by Subjective Angiographic Chemoembolization Endpoint (SACE) scale. Relative tumor density in arterial (DArt) and portal venous phase (DPV) computed tomography post- versus pre-DEB-TACE were calculated, respectively. Tumor response according to modified Response Criteria in Solid Tumors (mRECIST) was assessed. Univariate Kaplan-Meier and Cox regression analysis were carried out.
RESULTS: SACE scores I, II, III, and IV were found in 1 (2%), 20 (40%), 15 (30%), and 14 (28%) patients, respectively. Median OS and PFS were 14.2 and 5.5 months, respectively. Death rates at 6 months, 1 year and 2 years were 24%, 38%, and 52%, respectively. SACE score during DEB-TACE significantly correlated with local and overall mRECIST results (local: p < 0.001, r = 0.49, overall: p = 0.042, r = 0.29) and inversely correlated with DPV (p = 0.005, r = - 0.40). In univariate analysis, progressive disease (PD) according to mRECIST and increase of DArt and DPV were associated with significantly shorter PFS. Modified RECIST independently predicted OS (hazard ratio for complete remission vs. PD = 0.15, 95% confidence interval 0.03-0.68, p = 0.014).
CONCLUSIONS: A direct impact of SACE on PFS or OS could not be shown. However, SACE significantly correlated with local and overall mRECIST tumor response that again significantly predicted OS. We therefore postulate an indirect impact of SACE on OS. Consequently, complete embolization should be attempted.
引用
- Habbel VSA, Zeile M, Stavrou GA, et al. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma. Abdom Radiol (NY). 2019. PMID: 31332502. doi:10.1007/s00261-019-02128-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。